Search Results - "Pieterman, E J"

APOE3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome by van den Hoek, A. M., van der Hoorn, J. W. A., Maas, A. C., van den Hoogen, R. M., van Nieuwkoop, A., Droog, S., Offerman, E. H., Pieterman, E. J., Havekes, L. M., Princen, H. M. G.

“…Aims This study aimed to investigate systematically (i) the appropriate dietary conditions to induce the features of the MetS in APOE*3Leiden.humanCholesteryl…”
Get full text

Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP-1 and TIMP-3 by VAN DER LAAN, W. H, QUAX, P. H. A, HUIZINGA, T. W. J, PAP, T, SEEMAYER, C. A, HUISMAN, L. G. M, PIETERMAN, E. J, GRIMBERGEN, J. M, VERHEIJEN, J. H, BREEDVELD, F. C, GAY, R. E, GAY, S

“…Matrix metalloproteinases (MMPs) are believed to be pivotal enzymes in the invasion of articular cartilage by synovial tissue in rheumatoid arthritis (RA)…”
Get full text

Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE3Leiden.CETP mice--a translational model for atherosclerosis by Gierman, L M, Kühnast, S, Koudijs, A, Pieterman, E J, Kloppenburg, M, van Osch, G J V M, Stojanovic-Susulic, V, Huizinga, T W J, Princen, H M G, Zuurmond, A-M

“…Hypercholesterolaemia, a risk factor for atherosclerosis (ATH), has been suggested to have a role in the development of osteoarthritis (OA). To test this…”
Get more information

IL-1β inhibition combined with cholesterol-lowering therapies decreases synovial lining thickness and spontaneous cartilage degeneration in a humanized dyslipidemia mouse model by van Gemert, Y., Kruisbergen, N.N.L., Blom, A.B., van den Bosch, M.H.J., van der Kraan, P.M., Pieterman, E.J., Princen, H.M.G., van Lent, P.L.E.M.

“…Both systemic inflammation and dyslipidemia contribute to osteoarthritis (OA) development and have been suggested as a possible link between metabolic disease…”
Get full text

Novel high-intensive cholesterol-lowering therapies do not ameliorate knee OA development in humanized dyslipidemic mice by van Gemert, Y., Kozijn, A.E., Pouwer, M.G., Kruisbergen, N.N.L., van den Bosch, M.H.J., Blom, A.B., Pieterman, E.J., Weinans, H., Stoop, R., Princen, H.M.G., van Lent, P.L.E.M.

“…High systemic cholesterol levels have been associated with osteoarthritis (OA) development. Therefore, cholesterol lowering by statins has been suggested as a…”
Get full text

Intensive cholesterol-lowering treatment reduces synovial inflammation during early collagenase-induced osteoarthritis, but not pathology at end-stage disease in female dyslipidemic E3L.CETP mice by van Gemert, Y., Blom, A.B., Di Ceglie, I., Walgreen, B., Helsen, M., Sloetjes, A., Vogl, T., Roth, J., Kruisbergen, N.N.L., Pieterman, E.J., Princen, H.M.G., van der Kraan, P.M., van Lent, P.L.E.M., van den Bosch, M.H.J.

“…The association between metabolic syndrome (MetS) and osteoarthritis (OA) development has become increasingly recognized. In this context, the exact role of…”
Get full text

Variable cartilage degradation in mice with diet-induced metabolic dysfunction: food for thought by Kozijn, A.E., Gierman, L.M., van der Ham, F., Mulder, P., Morrison, M.C., Kühnast, S., van der Heijden, R.A., Stavro, P.M., van Koppen, A., Pieterman, E.J., van den Hoek, A.M., Kleemann, R., Princen, H.M.G., Mastbergen, S.C., Lafeber, F.P.J.G., Zuurmond, A.-M., Bobeldijk, I., Weinans, H., Stoop, R.

“…Human cohort studies have demonstrated a role for systemic metabolic dysfunction in osteoarthritis (OA) pathogenesis in obese patients. To explore the…”
Get full text

Association of the –2849 interleukin‐10 promoter polymorphism with autoantibody production and joint destruction in rheumatoid arthritis by Lard, L. R., van Gaalen, F. A., Schonkeren, J. J. M., Pieterman, E. J., Stoeken, G., Vos, K., Nelissen, R. G. H. H., Westendorp, R. G. J., Hoeben, R. C., Breedveld, F. C., Toes, R. E. M., Huizinga, T. W. J.

“…Objective To analyze the –2849 A/G interleukin‐10 (IL‐10) promoter polymorphism, which is associated with high (AG/GG) and low (AA) IL‐10 production, in a…”
Get full text

APOE 3Leiden . CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome by van den Hoek, A. M., van der Hoorn, J. W. A., Maas, A. C., van den Hoogen, R. M., van Nieuwkoop, A., Droog, S., Offerman, E. H., Pieterman, E. J., Havekes, L. M., Princen, H. M. G.

“…Aims This study aimed to investigate systematically (i) the appropriate dietary conditions to induce the features of the MetS in APOE * 3Leiden…”
Get full text

Oncostatin M reduces atherosclerosis development in APOE3Leiden.CETP mice and is associated with increased survival probability in humans by Keulen, Danielle van, Pouwer, Marianne G, Emilsson, Valur, Matic, Ljubica Perisic, Pieterman, Elsbet J, Hedin, Ulf, Gudnason, Vilmundur, Jennings, Lori L, Holmstrøm, Kim, Nielsen, Boye Schnack, Pasterkamp, Gerard, Lindeman, Jan H N, van Gool, Alain J, Sollewijn Gelpke, Maarten D, Princen, Hans M G, Tempel, Dennie

“…Previous studies indicate a role for Oncostatin M (OSM) in atherosclerosis and other chronic inflammatory diseases for which inhibitory antibodies are in…”
Get full text

Fibroblast-like synoviocytes from rheumatoid arthritis patients express less flice-inhibitory protein than FLS from osteoarthritis, trauma and prosthesis loosening patie by Tolboom, TCA, Medema, JP, Pieterman, EJ, Breedveld, FC, Huizinga, TWJ, Toes, REM

Get full text